A new risk assessment tool combining gene editing technology CRISPR-Cas9 with stem cells using disease modeling techniques has been developed by a team of scientists at the Stanford University Cardiovascular Institute. The tool has facilitated the modeling of individual patients’ heart in a lab and enabled undertaking of tests to ascertain whether or not signs of diseases are displayed by cardiac cells, as per a statement by the American Heart Association.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.